Loading…
Janux Therapeutics, Inc. is projected to rise to $20.39 by 2027, a +24% move from its current price of $16.40. JANX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $16.04 | $16.40 | $16.78 | +0.03% |
| Jul 14 | $15.89 | $16.41 | $16.94 | +0.05% |
| Jul 15 | $15.78 | $16.41 | $17.07 | +0.08% |
| Jul 16 | $15.69 | $16.42 | $17.18 | +0.11% |
| Jul 17 | $15.61 | $16.42 | $17.27 | +0.14% |
| Jul 18 | $15.54 | $16.43 | $17.36 | +0.16% |
| Jul 19 | $15.48 | $16.43 | $17.44 | +0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.48 | $16.43 | $17.44 | +0.19% |
| Week 2 | $15.13 | $16.46 | $17.91 | +0.38% |
| Week 3 | $14.87 | $16.49 | $18.29 | +0.57% |
| Week 4 | $14.66 | $16.53 | $18.62 | +0.77% |
| Week 5 | $14.49 | $16.56 | $18.93 | +0.96% |
| Week 6 | $14.33 | $16.59 | $19.20 | +1.15% |
| Week 7 | $14.19 | $16.62 | $19.47 | +1.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Janux Therapeutics, Inc. is a clinical stage biopharmaceutical company that develops immunotherapies based on TRACTr, TRACIr, and ARM platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a PSMA-TRACTr, in Phase 1 clinical trials for metastatic castration-resistant prostate cancer and the vasculature of other tumors; JANX008, an epidermal growth factor receptor targeted therapy in Phase 1 for various solid cancers; and JANX011, a CD19-targeted adaptive immune response modulator that is in Phase 1 for autoimmune diseases.
The company has strategic collaborations with Merck Sharp & Dohme Corp. to develop TRACTr product candidates and with Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc.
was incorporated in 2017 and is headquartered in San Diego, California.
Janux Therapeutics trades as JANX with a current price of $16.66 and a market capitalization of $1.02B, ranking 2538 by market position. The stock’s price outlook is positive over the long term, with forecasted averages rising from $16.66 in 2026 to $135.01 by 2050. The projections also show a path of increasing upside, with the 2050 average price supporting a ROI of 710.4%.
A major floor 27.8% below — a decisive break under it would weaken the trend.
The nearest floor, 19.8% below — buyers have tended to step in here.
Price is pressing into resistance (2.1% away) — a breakout level to watch.
A major ceiling 16.1% above — clearing it would confirm fresh momentum.
Key JANX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JANX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.27 | Buy | $16.26 | Buy |
| MA 10 | $15.72 | Buy | $15.81 | Buy |
| MA 20 | $14.93 | Buy | $15.25 | Buy |
| MA 50 | $14.47 | Buy | $14.75 | Buy |
| MA 100 | $14.34 | Buy | $15.12 | Buy |
| MA 200 | $17.45 | Sell | $17.60 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 65.78 | Neutral |
| Stoch RSI (14) | 69.09 | Neutral |
| CCI (20) | 120.27 | Buy |
| Williams %R (14) | -14.52 | Info |
| MACD (12,26,9) | 0.21 | Buy |
| ROC (12) | 9.99 | Buy |
| Bollinger %B (20,2) | 0.88 | Neutral |
| Stochastic %K (14) | 85.48 | Sell |
| TRIX (15) | 0.37 | Buy |
| Awesome (5,34) | 1.72 | Buy |
| Ultimate (7,14,28) | 66.19 | Neutral |
| Momentum (10) | 1.82 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 16.92 | Sell |
| ADX (14) | 22.02 | Buy |
| ATR (14) | 0.33 | Info |
The 30-day technical picture is bullish with RSI(14) at 70, indicating strong momentum. The stock’s 50-day simple moving average is $14.40 and the 200-day simple moving average is $17.52, providing near-term dynamic levels. Support is indicated at $13.15 and resistance at $16.66, while the 30-day price range spans from $14.26 to $19.46.
Annualized volatility is high at 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.18 | $16.40 | $22.41 | 0% | Neutral | |
| $16.49 | $20.39 | $26.50 | +24% | Bullish | |
| $17.85 | $22.58 | $30.28 | +38% | Bullish | |
| $18.18 | $23.42 | $32.19 | +43% | Bullish | |
| $20.13 | $26.36 | $37.00 | +61% | Bullish | |
| $22.48 | $29.88 | $42.71 | +82% | Bullish | |
| $24.40 | $32.90 | $47.80 | +101% | Bullish | |
| $29.57 | $40.38 | $59.55 | +146% | Bullish | |
| $32.19 | $44.50 | $66.54 | +171% | Bullish | |
| $32.08 | $44.87 | $67.95 | +174% | Bullish | |
| $47.86 | $70.55 | $112.74 | +330% | Bullish | |
| $82.64 | $133.13 | $230.27 | +712% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.18 | $16.40 | $19.51 | +0.00% |
| August 2026 | $13.90 | $16.33 | $19.65 | -0.40% |
| September 2026 | $14.23 | $16.81 | $20.41 | +2.92% |
| October 2026 | $14.82 | $17.60 | $21.53 | +4.67% |
| November 2026 | $14.97 | $17.85 | $21.98 | +1.41% |
| December 2026 | $15.11 | $18.08 | $22.41 | +1.34% |
Click any year to see its month-by-month JANX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, JANX could reach as high as $22.41, with a base case around $16.40 and support toward $12.18 — roughly 0% from $16.40. Price action looks broadly range-bound.
Expect JANX to range from $16.49 to $26.50 through 2027. The $20.39 average target implies a +24% move from current prices. That is up +24% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The JANX price prediction for 2028 points to an average of $22.58 (low $17.85, high $30.28) — a potential gain of +38% on today's $16.40. Momentum favours further upside here.
In 2029, JANX is projected to trade between $18.18 and $32.19, averaging $23.42 — a potential gain of +43% from today's $16.40. That is up +4% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Janux Therapeutics, Inc.'s 2030 outlook centres on $26.36, within a $20.13 to $37.00 range. That is up +13% on the projected 2029 average. That marks a +61% change versus current levels. Momentum favours further upside here.
By 2031, JANX could reach as high as $42.71, with a base case around $29.88 and support toward $22.48 — roughly +82% from $16.40. Buyers look set to stay in control over this stretch.
Expect JANX to range from $24.40 to $47.80 through 2032. The $32.90 average target implies a +101% move from current prices. That is up +10% on the projected 2031 average. Momentum favours further upside here.
The JANX price prediction for 2033 points to an average of $40.38 (low $29.57, high $59.55) — a potential gain of +146% on today's $16.40. Buyers look set to stay in control over this stretch.
In 2034, JANX is projected to trade between $32.19 and $66.54, averaging $44.50 — a potential gain of +171% from today's $16.40. That is up +10% on the projected 2033 average. Momentum favours further upside here.
Janux Therapeutics, Inc.'s 2035 outlook centres on $44.87, within a $32.08 to $67.95 range. That is up +1% on the projected 2034 average. That marks a +174% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, JANX could reach as high as $112.74, with a base case around $70.55 and support toward $47.86 — roughly +330% from $16.40. Momentum favours further upside here.
Expect JANX to range from $82.64 to $230.27 through 2050. The $133.13 average target implies a +712% move from current prices. That is up +89% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in JANX today (≈ 60.97561 JANX) could be worth
$8,117.67
+$7,117.67 (+712%) by 2050 · US Dollar
Based on the average projected JANX price of $133.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JANXwould be worth at today's price.
$1,000 invested in JANX on Jul 10, 2025 (≈ 39.047246 JANX) would be worth
$640.37
-$359.63 (-36.0%) today · 0.64× · US Dollar
Based on a JANX entry price of $25.61 vs. today's $16.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $15.54 | $1,055.34 | +5.5% |
| 1 month ago | $13.15 | $1,247.15 | +24.7% |
| 3 months ago | $14.93 | $1,098.46 | +9.8% |
| 6 months ago | $14.03 | $1,168.92 | +16.9% |
| 1 year ago | $25.61 | $640.37 | -36.0% |
| All time (5.0y) ago | $27.35 | $599.63 | -40.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JANX forecast.
Our base-case forecast reaches $33.00 around 2033.
Implied market cap at $33.00: $2.01B
The multi-year forecast shows a rising price trajectory, with the 2030 average price at $26.73 and a min of $20.28 and max of $37.80, yielding a 60.4% ROI and a bullish sentiment. By 2040, the average is projected at $71.39 with a 328.5% ROI, continuing the bullish stance. By 2050, the average climbs to $135.01 with a 710.4% ROI, maintaining a bullish outlook.
The forecast highlights a long-term upside potential but remains an estimate rather than a guarantee. The implied path suggests higher price levels in later years, complemented by sustained bullish sentiment across the forecast horizon.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $26.73 with a range from $20.28 to $37.80 and a ROI of 60.4%, with a bullish sentiment.
Long-term projections indicate upside, with 2030 average at $26.73, 2040 at $71.39, and 2050 at $135.01, delivering up to 710.4% ROI and a bullish outlook.
Yes. The 2050 average price is $135.01, which is above $100.
The current price is $16.66.
The 30-day range is from $14.26 to $19.46.
Janux Therapeutics, Inc. Community Discussion
0Share your Janux Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.